23andMe raises nearly $85M: 4 things to know  

Direct-to-consumer DNA testing company 23andMe has raised almost $85 million this month, according to a Dec. 28 Silicon Valley Business Journal report. 

Four things to know: 

1. The financing will be used for general corporate purposes, a company spokesperson told the publication, adding that Sequoia Capital and NewView Capital led the investment round. 

2. The new funding comes nearly a year after 23andMe announced layoffs of 100 employees due to decreasing sales of its direct-to-consumer DNA test kits. 

3. At a conference earlier in December, 23andMe CEO Anne Wojcicki said more than 12 million of the company's customers agreed to participate in drug discovery research, which helped support COVID-19 research. 

4. More than one million people took 23andMe's COVID-19 study, which found that people with O blood type are between 9 percent and 18 percent less likely than others to have tested positive for COVID-19. 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars